Search bioRxivSearch

Biology subjects

LeBlond, N. D.

Publications and source records attributed to LeBlond, N. D..

2 recordsLinked to original sources

Fatty acid-induced lipotoxicity inhibits choline metabolism independent of ER stress in mouse primary hepatocytes

Choline is an essential nutrient that is critical component of the membrane phospholipid phosphatidylcholine (PC), the neurotransmitter acetylcholine and the methylation pathway. In the liver specifically, PC is the major membrane constituent and can be synthesized by the CDP-choline or the phosphatidylethanolamine (PE) N-methyltransferase (PEMT) pathway. With the continuing global rise in the rates of obesity and non-alcoholic fatty liver disease, we sought to explore how excess fatty acids (FA), typical of an obesity and hepatic steatosis, affect choline uptake and metabolism in primary hepatocytes. Our results demonstrate that hepatocytes chronically treated with palmitate, but not oleate or a mixture, had decreased choline uptake, which was associated with lower choline incorporation into PC and lower expression of choline transport proteins. Interestingly, a reduction in the rate of degradation spared PC levels in response to palmitate when compared to control. PE synthesis was slightly diminished; however, no compensatory changes in the PEMT pathway were observed. We next hypothesized that ER stress may be a potential mechanism by which palmitate treatment diminished choline. However, when we exposed primary hepatocytes to the common ER stress inducing compound tunicamycin, choline uptake, contrary to our expectation was augmented, concomitant with the transcript expression of choline transporters. Moreover, tunicamycin-induced ER stress divorced the observed increase in choline uptake from CDP-choline pathway flux since ER stress significantly diminished the incorporation and total PC content, similar to PE. Conclusion: Therefore, our results suggest that the altered FA milieu seen in obesity and fatty liver disease progression may adversely affect choline metabolism, but that compensatory mechanisms work to maintain phospholipid homeostasis.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=175 SRC=\"FIGDIR/small/746750v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (42K):\norg.highwire.dtl.DTLVardef@1090f2aorg.highwire.dtl.DTLVardef@1c28eedorg.highwire.dtl.DTLVardef@35a80eorg.highwire.dtl.DTLVardef@ac5a53_HPS_FORMAT_FIGEXP M_FIG C_FIG

cell biology

Characterization of LXR-activating nanoparticle formulations in primary mouse macrophages

Activation of the transcription factor liver X receptor (LXR), has shown to be efficient at curbing aberrant lipid metabolism and inflammation. While small molecule delivery via nanomedicine has promising applications for a number of chronic diseases, there remain questions as to how nanoparticle formulation might be tailored to suit different tissue microenvironments and aid in drug delivery. In the current study, we compared the drug delivery capability of three nanoparticle (NP) formulations encapsulating the LXR activator, GW-3956. We observed little difference in the base characteristics of standard PLGA-PEG NP when compared to two redox-active polymeric NP formulations (DD and DB). Moreover, we also observed similar uptake of these NP into primary mouse macrophages. After an initial acute uptake period and using the transcript and protein expression of the cholesterol efflux protein ATP binding cassette A1 (ABCA1) as a readout, we determined that while the induction of transcript expression was similar between NPs, treatment with the redox-sensitive DB formulation resulted in a higher level of ABCA1 protein 24 h after the removal of the drug-containing NPs. Our results suggest that NP formulations responsive to cellular cues may be an effective tool for targeted and disease-specific drug release.

biochemistry